OTPE CONTROL OF THE PROPERTY O

Patent Application Attorney Docket No. 210895ANIS

by the position of the positio

Janice Denison
(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.: 10/040,570

In Re Application of Martyn Frank

Burslem

Filed: November 1, 2001 Group Art Unit: 1632

Examiner: Valarie E. Bertoglio Docket No.: PCS10895ANIS

Customer No.: 28523

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

<u>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</u> <u>PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.</u>

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Patent Application Attorney Docket No.PCS10895ANIS

A prompt and favorable response is earnestly solicited.

Date: Sypt. 29"2003

Deborah A. Martin

Respectfully submitted,

Attorney for Applicant(s)

Reg. No. 44,222

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-1821

											_	7/1	~	
INFORMATION DISCLOSURE CITATION ATTY. DOCKET NO. PCS10895A)895ANIS	SERIAL N	5024010	40.5)—— 70
(Use several sheets if necessary)							APPLICANT Martyn Frank Burslem						10,37	<u>-</u>
							LING DA			GROUP 1600,4632				
EXAMINER INITIAL		<u></u>				U.:	S. PATE	NT DOC	UMENTS			100		
INITIAL	HADE	DOCUMENT NUMBER				JMBER			DATE	NAME	CLASS	SUBCLASS	S FILING DATE	
	US 0		0	0 2	5	99	6	9	02/28/02	Forssmann, e	tal. A61K	31/47		- NOFRIA
			<u> </u>								7.0110	31/47	1-	
						FORE	IGN PAT	TENT D	OCUMEN.	 TS			<u> </u>	
DOCUMENT NUMBER									DATE					
									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
	EP	0	4	6	3	7						 	YES	NO
	EP	0					5	6	06/07/91	International	C07D	487/04		-
			5	7_	9	4	9	6	07/15/93	International	C07D	401/04		<u> </u>
	EP	0	6	0	7	4	3	9	09/30/92	International	C07D	215/00		
	wo	9	5	1	9	9	7	8	07/27/95	International	C07D	471/14		
	wo	9	9	0	2	1	6	1 ,	01/21/99	International	A61K	31/52		
		-,	ОТН	ER DOC	UMEN	rs (Inc	luding A	uthor, Ti	itle, Date, i	Pertinent Page	es, Etc.)	1 01/02		
		Kodam	ıa, K., et	al <i>Effect:</i>	s of a nov	el selec	tive and no	tont nh						
	-	Kodama, K., et al., Effects of a novel, selective and potent phosphodiesterase type V inhibitor, E4021, on myocardial ischemia in guinea pigs, Euro. Journal of Pharm., Vol. 263: 93-99, 1994												n
		Kühn, R., et al., Relaxation of human ureteral smooth muscle in vitro by modulation of cyclic nucleotide-dependent pathways, Urol												
		Lee, S., et al., Discovery of potent cyclic CMD phase to discovery												
	+-	Lee, S., et al., Discovery of potent cyclic GMP phosphodiesterase inhibitors, 2-pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and thromboxane synthesis inhibitory activities, J. Med. Chem., Vol. 38: 3547-3557, 1995												
	 	Middendorff, R., et al., Multiple roles of the messenger molecule cGMP in testicular function, Andrologia, Vol. 32(1): 55-59, 2000												
		Truss, M., et al., Selective pharmacological manipulation of the smooth muscle tissue of the genitourinary tract: a glimpse into the future, BJU International, Vol. 83(2): 36-41, 1999												
					J. 00(Z).	30-41,	1338							
														
XAMINER							l	DATE CO	NSIDERED					
			 .											
AMINER: Init d communica	tial if refe tion to ap	rence consid	ered, wheth	er or not citat	ion is in confe	ormance w	ith MPEP 609;	Draw line the	rough citation if n	ot in conformance and	not considered. Incl	lude copy of this f	orm with	
												.,		- 1

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE